PROCEPT BioRobotics Corp

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

PRCT$23.05+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity F-

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands)

Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveGain (Loss) · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount
Balance at December 31, 2021	43,676	$—	$528,666	$(54)		$(261,521)		267,091
Issuance of common stock under stock plans	1,152	—	6,417	—		—		6,417
Stock-based compensation expense	—	—	10,670	—		—		10,670
Unrealized gain on cash equivalents	—	—	—	48		—		48
Net loss	—	—	—		(87,154)		(87,154)
Balance at December 31, 2022	44,828	—	545,753	(6)		(348,675)		197,072
Issuance of common stock under stock plans	858	—	6,090	—		—		6,090
Issuance of common stock, net of issuance costs of $10,795	5,085	—	161,705	—		—		161,705
Stock-based compensation expense	—	—	21,692	—		—		21,692
Unrealized gain on cash equivalents	—	—	—	90		—		90
Net loss	—	—	—	—		(105,897)		(105,897)
Balance at December 31, 2023	50,771	$—	735,240	84		(454,572)		280,752
Issuance of common stock under stock plans	2,024	—	15,602	—		—		15,602
Issuance of common stock, net of issuance cost of $11,282	1,923	—	164,523	—		—		164,523
Stock-based compensation expense	—	—	32,726	—		—		32,726
Unrealized gain on cash equivalents	—	—	—	30		—		30
Net loss	—	—	—	—		(91,413)		(91,413)
Balance at December 31, 2024	54,718	$—	$948,091	$114		$(545,985)		$402,220

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.